AAIPharma to offer 'one-stop shop' for drug development

By Emilie Reymond

- Last updated on GMT

Related tags: Pharmacology

AAIPharma has announced it has signed a contract manufacturing
agreement with Mallinckrodt Pharmaceuticals Outsourcing which aims
to provide a "one-stop drug development solution" for drug makers.

The agreement sees the contract manufacturers pool their resources to offer pharma and biotech companies a complementary service, from formulation and early stage analysis through to large scale manufacturing.

North Carolina-based AAIPharma provides formulation and early stage analysis through clinical trials while Mallinckrodt, based in Missouri, is a global manufacturer and marketer of healthcare products in the areas of respiratory care, imaging, and analgesic pharmaceuticals.

Therefore, what Mallinckrodt brings to the deal is large-scale manufacturing, which is a service AAI does not provide.

"This alliance significantly strengthens our ability to meet the commercial manufacturing needs of our customers worldwide,"​ said Vito Mangiardi, AAIPharma president of North American Operations.

"Combining AAIPharma and Mallinckrodt's expertise will create competitive advantages for both companies and expand respective business opportunities."

Taking a product from early-phase drug formulation to high-volume commercial manufacturing can be challenging as it involves a number of steps as well as complex technical transfers and this new alliance could prove highly attractive to drug companies, as it will provide a one-stop shop for drug development.

According to AAIPharma, this collaboration will allow it to seamlessly carry its clients from concept through production.

This partnership comes weeks after AAIPharma's acquisition of French cancer-research company Cvitkovic & Associes Consultants, which was announced in September and completed on 26 October.

The road has been rocky for AAIPharma of late as the company filed for bankruptcy last year after being plagued for a year by questions over accountancy fraud.

After narrowly escaping liquidation, the troubled firm undertook a reshuffle under Chapter 11 bankrupcty protection earlier this year and sold off its pharmaceutical products division to concentrate purely on clinical research, hoping the purchase of CAC will set it on the road to recovery.

Related news

Show more

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 19-Oct-2020 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 21-Sep-2020 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

Related suppliers

Follow us


View more